Cardiovascular and Mortality Outcomes with JAK versus TNF Inhibitors in Rheumatoid Arthritis: A Target Trial Emulation (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1900; Pres time: Nov 9, 2026; 03:30 PM - 03:45 PM; Location: W109; In Person; "JAKi initiation was associated with modest excesses in all-cause mortality and HF hospitalization versus TNFi, but no excess in MACE. Heterogeneity was clinically relevant: upadacitinib showed no excess, whereas tofacitinib and baricitinib each carried significant mortality signals. The null MACE result should not be read as class-wide safety reassurance."
Cardiovascular • Congestive Heart Failure • Heart Failure • Immunology • Inflammatory Arthritis • Ischemic stroke • Myocardial Infarction • Rheumatoid Arthritis • Rheumatology • Venous Thromboembolism
|
|
Laith Alamlih1; Rachael McClenahan2
|